<DOC>
	<DOCNO>NCT01591135</DOCNO>
	<brief_summary>The primary objective trial study whether paclitaxel plus 5-fluorouracil good overall survival cisplatin plus 5-fluorouracil chemoradiotherapy patient locally advanced esophageal squamous cell carcinoma . 436 patient recruit study .</brief_summary>
	<brief_title>A Phase III Study Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil Chemoradiotherapy Locally Advanced Esophageal Carcinoma</brief_title>
	<detailed_description>Locally advanced esophageal squamous cell carcinoma . T2-4N0-1M0-1a , TxN1M0-1a，TxNxM1a （according AJCC2002） Scheme : Eligible recurrent patient esophageal cancer first stratify nodal staging ( N0 N1 ) , randomize 2 arm 1:1 ratio . Arm Cisplatin : Chemoradiotherapy cisplatin 5-fluorouracil 4 cycle . Arm Paclitaxel : Chemoradiotherapy weekly paclitaxel 5-fluorouracil 5 week follow adjuvant chemotherapy 2 cycle .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Joined study voluntarily sign informed consent form ; Age 1875 Both gender Esophageal squamous cell carcinoma confirm pathology Local advance esophageal squamous cell carcinoma ( T2N0M0TxNxM1a , AJCC 2002 ) No radiotherapy , chemotherapy treatment prior enrollment PS ECOG 02 Life expectancy 3 month Hemoglobin（Hb）≥9 g/dL WBC≥3x109/L , Neutrophils ( ANC ) ≥1.5x109/L platelet count ( Pt ) ≥100x 109/L Hepatic function : ALAT ASAT &lt; 2.5 x ULN , TBIL &lt; 1.5 x ULN Renal function : creatinine &lt; 1.5 x ULN No immunodeficiency Use effective contraceptive adult prevent pregnancy . Complete esophageal obstruction Deep esophageal ulcer Esophageal perforation Haematemesis After surgery , exploratory thoracotomy , radiotherapy , chemotherapy , target therapy Other malignant tumor , except skin basal cell carcinoma , cervical carcinoma situ , survive evidence disease 3 year Participation interventional clinical trial within 30 day Pregnant breastfeed woman people birthperiod refused take contraceptive Drug addiction Alcoholism AIDS Uncontrolled seizure psychiatric disease , loss control behavior Patient metastasis lung , liver metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Esophageal squamous cell carcinoma</keyword>
	<keyword>chemoradiotherapy</keyword>
</DOC>